Phase III, randomized, placebo-controlled study of once-daily oral zibotentan (ZD4054) in patients with non-metastatic castration-resistant prostate cancer

被引：0
|
作者：
K Miller
J W Moul
M Gleave
K Fizazi
J B Nelson
T Morris
F E Nathan
S McIntosh
K Pemberton
C S Higano
机构：
[1] Charité–Universitätsmedizin Berlin,Department of Urology
[2] Duke Cancer Institute,Division of Urology, Department of Surgery and Duke Prostate Center
[3] Duke University Medical Center,Department of Urology
[4] Vancouver Prostate Center,undefined
[5] University of British Columbia,undefined
[6] Institut Gustave Roussy,undefined
[7] University of Paris Sud,undefined
[8] University of Pittsburgh School of Medicine,undefined
[9] AstraZeneca,undefined
[10] AstraZeneca Pharmaceuticals LP,undefined
[11] Fred Hutchinson Cancer Research Center,undefined
[12] University of Washington School of Medicine,undefined
来源：
Prostate Cancer and Prostatic Diseases | 2013年 / 16卷
关键词：
zibotentan; ZD4054; non-metastatic; castration-resistant;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：187 / 192
页数：5
相关论文
共 50 条
  • [21] Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: Safety analyses from the randomized, placebo-controlled, phase III TALAPRO-2 study
    Azad, Arun A.
    Fizazi, Karim
    Matsubara, Nobuaki
    Saad, Fred
    De Giorgi, Ugo
    Joung, Jae Young
    Fong, Peter C. C.
    Jones, Robert J.
    Zschaebitz, Stefanie
    Oldenburg, Jan
    Shore, Neal D.
    Dunshee, Curtis
    Carles, Joan
    Fay, Andre P.
    Lin, Xun
    Deannuntis, Liza
    Di Santo, Nicola
    Zielinski, Michael A.
    Agarwal, Neeraj
    EUROPEAN JOURNAL OF CANCER, 2024, 213
  • [22] Current opportunities of therapy for patients with non-metastatic castration-resistant prostate cancer
    Alekseev, B. Ya
    Nushko, K. M.
    Kozlova, P. S.
    Kaprin, A. D.
    Mailyan, O., I
    ONKOUROLOGIYA, 2020, 16 (03): : 190 - 197
  • [23] Clinical characteristics and outcomes for patients with non-metastatic castration-resistant prostate cancer
    Arnold, Peter
    Penaloza-Ramos, Maria Cristina
    Adedokun, Lola
    Rees, Sarah
    Lockhat, Mohamed
    Spary, Lisa
    Watkins, Alan
    Gnanapragasam, Vincent
    Crabb, Simon J.
    SCIENTIFIC REPORTS, 2021, 11 (01)
  • [24] New treatment standard for patients with non-metastatic castration-resistant prostate cancer
    Alekseev, B. Ya
    ONKOUROLOGIYA, 2018, 14 (03): : 68 - 77
  • [25] PROSPER: A Phase 3, Randomized, Double-Blind, Placebo (PBO)-Controlled Study of Enzalutamide (ENZA) in Menwith Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC)
    Stockler, M. R.
    Hussain, M.
    Fizazi, K.
    Saad, F.
    Rathenborg, P.
    Shore, N.
    Demirhan, E.
    Modelska, K.
    Phung, D.
    Krivoshik, A.
    Sternberg, C. N.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2018, 14 : 53 - 54
  • [26] Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trial
    Saad, Fred
    Cella, David
    Basch, Ethan
    Hadaschik, Boris A.
    Mainwaring, Paul N.
    Oudard, Stephane
    Graff, Julie N.
    McQuarrie, Kelly
    Li, Susan
    Hudgens, Stacie
    Lawson, Joe
    Lopez-Gitlitz, Angela
    Yu, Margaret K.
    Smith, Matthew R.
    Small, Eric J.
    LANCET ONCOLOGY, 2018, 19 (10): : 1404 - 1416
  • [27] Detection of metastatic disease as a leading cause of screening failure in a phase III trial of zibotentan versus placebo in patients with nonmetastatic castration-resistant prostate cancer (CRPC).
    Yu, E. Y.
    Nathan, F. E.
    Higano, C. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [28] PELVIC EXENTERATION IN PATIENTS WITH NON-METASTATIC, LOCALLY ADVANCED CASTRATION-RESISTANT PROSTATE CANCER
    Donahue, Timothy F.
    Morris, Michael J.
    Slovin, Susan F.
    Scher, Howard I.
    Scardino, Peter T.
    Bochner, Bernard H.
    JOURNAL OF UROLOGY, 2015, 193 (04): : E1038 - E1038
  • [29] Adverse events and costs among non-metastatic castration-resistant prostate cancer patients
    Appukkuttan, Sreevalsa
    Yao, Jianying
    Partridge, Jamie
    Kong, Sheldon X.
    Parkin, Jacqueline
    Freedland, Stephen J.
    JOURNAL OF MEDICAL ECONOMICS, 2024, 27 (01) : 145 - 152
  • [30] Does docetaxel prolong survival of patients with non-metastatic castration-resistant prostate cancer?
    Ito, Kagenori
    Kimura, Takahiro
    Onuma, Hajime
    Tabata, Ryuji
    Shimomura, Tatsuya
    Miki, Kenta
    Tomita, Masayuki
    Egawa, Shin
    PROSTATE, 2018, 78 (07): : 498 - 505
12345